This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:tests:lipids [11.05.2010] – external 127.0.0.1 | home:tests:lipids [04.16.2015] – [Atherosclerosis] joyful | ||
---|---|---|---|
Line 7: | Line 7: | ||
* triglycerides | * triglycerides | ||
- | In many of the diseases the Marshall Protocol (MP) treats, patients may present with elevated cholesterol. Traditionally, | + | In many of the diseases the Marshall Protocol (MP) treats, patients may present with elevated cholesterol. Traditionally, |
Both " | Both " | ||
Line 28: | Line 28: | ||
Both " | Both " | ||
- | There is also broad evidence that cholesterol does not promote plaque as evidenced by studies that show therapies which directly lower cholesterol may make patients sicker. The article devoted to [[home: | + | There is also broad evidence that cholesterol does not promote plaque as evidenced by studies that show therapies which directly lower cholesterol may make patients sicker. The article devoted to [[home: |
Some patients on the Marshall Protocol (MP) have reported temporary increases in cholesterol and triglycerides, | Some patients on the Marshall Protocol (MP) have reported temporary increases in cholesterol and triglycerides, | ||
Line 37: | Line 37: | ||
===== Statins and other anti-cholesterol drugs ===== | ===== Statins and other anti-cholesterol drugs ===== | ||
- | < | + | < |
{{section>: | {{section>: | ||
Line 84: | Line 84: | ||
* **Some angiographic studies show that cholesterol is // | * **Some angiographic studies show that cholesterol is // | ||
- | * **Diets intended to lower cholesterol do not lead to atherosclerosis** – In 2006, the Cochrane Collaboration published an update of a systematic review that analyzed 10 of the most rigorous studies to test the ability of " | + | * **Diets intended to lower cholesterol do not lead to reduced |
Line 125: | Line 125: | ||
</ | </ | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||
- | TECHEDIT | + | |
* Legacy content | * Legacy content | ||
Line 131: | Line 131: | ||
+ | < | ||
+ | |||
+ | http:// | ||
+ | |||
+ | Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds | ||
+ | Abstract | ||
+ | |||
+ | People aged 80 or older are the fastest growing population in high-income countries. One of the most common causes of death among the elderly is the cardiovascular disease (CVD). Lipid-lowering treatment is common, e.g. one-third of 75–84-year-old Swedes are treated with statins [ 3]. The assumption that hypercholesterolaemia is a risk factor at the highest ages seems to be based on extrapolation from younger adults. A review of observational studies shows a trend where all-cause mortality was highest when total cholesterol (TC) was lowest (‘a reverse J-shaped’ association between TC and all-cause mortality). Low TC (<5.5 mmol/l) is associated with the highest mortality rate in 80+-year olds. No clear optimal level of TC was identified. A review of the few randomised controlled trials including 80+-year olds did not provide evidence of an effect of lipid-lowering treatment on total mortality in 80+-year-old people. There is not sufficient data to recommend anything regarding initiation or continuation of lipid-lowering treatment for the population aged 80+, with known CVD, and it is even possible that statins may increase all-cause mortality in this group of elderly individuals without CVD.</ | ||
===== References ===== | ===== References ===== |